Leica Biosystems, a global leader in anatomic pathology laboratory solutions and instruments, has successfully completed its previously announced acquisition of breast biopsy instruments and consumables business, Devicor Medical Products, Inc.
Devicor is committed to advancing technology to help clinicians accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures. Among Devicor’s products is the Original Mammotome Breast Biopsy System, which, to date, has enabled more than four million women to have a minimally invasive breast biopsy.
Devicor’s annual revenues are approximately $170 million. Following acquisition, Devicor will operate as a standalone business within Leica Biosystems and will continue to be led by Tom Daulton, the current CEO of Devicor.
No other financial terms and conditions have been disclosed.
“Leica’s Biosystems’ products and solutions address the key steps across the anatomic pathology laboratory workflow. The addition of Devicor’s market leading breast biopsy products, especially Mammotome, allows us to further integrate that workflow from the source, starting with the patient and the biopsy sample,” said Matthias Weber, MD, President of Leica Biosystems. “This acquisition supports our mission of advancing cancer diagnostics to improve lives by adding products that will have direct benefits for the patients and the clinicians who care for them.”
Source: Leica Biosystems